PARIS, France and TARRYTOWN, NY, USA I April 18, 2025 I The US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for the treatment of ...

HONG KONG, China I April 18, 2025 I Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that ebdarokimab, an investigational monoclonal ...

LONDON, UK I April 17, 2025 I GSK plc (LSE/NYSE: GSK) today announced the authorisation of Blenrep by the Medicines and Healthcare products Regulatory Agency ...

NORTHBROOK, IL, USA I April 17, 2025 I Endevica Bio, a privately held company developing first-in-class peptide drug candidates, announced today the dose ...

BUFFALO, NY, USA I April 17, 2025 I As H5N1 avian influenza continues its spread across species and continents, a vaccine being developed by University of ...

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development. La Merie Publishing offers an e-mail notification service about the release of new products ...

BRIDGEWATER, NJ, USA and BENGALURU, Karnataka, India I April 15, 2025 I Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and ...

Collaboration partner, Gilead Sciences, to begin Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) study in healthy volunteers in Q2 2025 ...

GENEVA, Switzerland I April 17, 2025 I Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of ...

SAN DIEGO, CA, USA I April 17, 2025 I Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company pioneering targeted ...

Collaboration combines BigHat's AL/ML-powered Milliner™ platform with Lilly's expertise in drug discovery to develop high-quality next-generation antibodies.

INGELHEIM, Germany, and BOSTON, MA, USA I April 14, 2025 I Boehringer Ingelheim and Cue Biopharma, Inc. (Nasdaq: CUE) today announced a strategic research ...